Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis
Michelle Sholzberg, Bruno R. da Costa, Grace H. Tang, et al.
Research and Practice in Thrombosis and Haemostasis (2021) Vol. 5, Iss. 8, pp. e12638-e12638
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

ISTH guidelines for antithrombotic treatment in COVID‐19
Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 10, pp. 2214-2225
Open Access | Times Cited: 145
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Sam Schulman, Donald M. Arnold, Charlotte Bradbury, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 6, pp. 1779-1797
Open Access | Times Cited: 18
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients
Adam Cuker, Eric Tseng, Robby Nieuwlaat, et al.
Blood Advances (2022) Vol. 6, Iss. 17, pp. 4915-4923
Open Access | Times Cited: 56
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Barco, Davide Voci, Ulrike Held, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 8, pp. e585-e593
Open Access | Times Cited: 48
Clinical features of thrombosis and bleeding in COVID-19
Mari R. Thomas, Marie Scully
Blood (2022) Vol. 140, Iss. 3, pp. 184-195
Open Access | Times Cited: 41
Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia
Vincent Labbé, Damien Contou, Nicholas Heming, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 6, pp. 520-520
Open Access | Times Cited: 21
Current Effective Therapeutics in Management of COVID-19
Kavya Atluri, Iris Aimlin, Shitij Arora
Journal of Clinical Medicine (2022) Vol. 11, Iss. 13, pp. 3838-3838
Open Access | Times Cited: 31
COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment
Luis Ortega‐Paz, Azita H. Talasaz, Parham Sadeghipour, et al.
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 08, pp. 816-832
Open Access | Times Cited: 28
Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area
Davide Voci, Ugo Fedeli, Ioannis T. Farmakis, et al.
Thrombosis Research (2022) Vol. 212, pp. 44-50
Open Access | Times Cited: 23
D‐dimer testing in clinical practice in the era of COVID‐19
Claire Auditeau, Lina Khider, Benjamin Planquette, et al.
Research and Practice in Thrombosis and Haemostasis (2022) Vol. 6, Iss. 4, pp. e12730-e12730
Open Access | Times Cited: 22
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials
Eros Pilia, Alessandro Belletti, Stefano Fresilli, et al.
Journal of Thrombosis and Thrombolysis (2022) Vol. 54, Iss. 3, pp. 420-430
Open Access | Times Cited: 20
Anticoagulation in hospitalized patients with COVID-19
Lisa Baumann Kreuziger, Michelle Sholzberg, Mary Cushman
Blood (2022) Vol. 140, Iss. 8, pp. 809-814
Open Access | Times Cited: 19
The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies
Eros Pilia, Alessandro Belletti, Stefano Fresilli, et al.
Lung (2023) Vol. 201, Iss. 2, pp. 135-147
Open Access | Times Cited: 10
The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics
Friederike Eilts, Sarah Bauer, Keith Fraser, et al.
Carbohydrate Polymers (2022) Vol. 299, pp. 120167-120167
Open Access | Times Cited: 14
Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials
Luana Caroline Miantti Ghellere Bonfim, Isadora Schwaab Guerini, Marjorie G. Zambon, et al.
Journal of Critical Care (2023) Vol. 77, pp. 154344-154344
Open Access | Times Cited: 5
Cerebrovascular Disease in COVID-19
James E. Siegler, Savanna Dasgupta, Mohamad Abdalkader, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1598-1598
Open Access | Times Cited: 5
Evaluation of a fast‐and‐frugal clinical decision algorithm (‘pathways’) on clinical outcomes in hospitalised patients with COVID‐19 treated with anticoagulants
Benjamin Djulbegović, Iztok Hozo, David Lizarraga, et al.
Journal of Evaluation in Clinical Practice (2022) Vol. 29, Iss. 1, pp. 3-12
Open Access | Times Cited: 9
“ISTH guidelines for antithrombotic treatment in COVID‐19”: Reply
Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 11, pp. 2710-2711
Open Access | Times Cited: 9
Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19
Lucas C. Godoy, Matthew D. Neal, Ewan C. Goligher, et al.
JACC Advances (2024) Vol. 3, Iss. 3, pp. 100780-100780
Open Access | Times Cited: 1
Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis
Lorenzo Loffredo, Augusto Di Castelnuovo, Giovanni Alfonso Chiariello, et al.
Haematologica (2022) Vol. 107, Iss. 8, pp. 1933-1939
Open Access | Times Cited: 8
Anticoagulant Treatment in Severe ARDS COVID-19 Patients
Adrián Ceccato, Marta Camprubí‐Rimblas, Elena Campaña-Duel, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 10, pp. 2695-2695
Open Access | Times Cited: 8
Dysregulated thrombospondin 1 and miRNA-29a-3p in severe COVID-19
In Soo Kim, Sung‐Gwon Lee, Seul Gi Shin, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 7
Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
Matthias M. Engelen, Christophe Vandenbriele, Valérie Spalart, et al.
Research and Practice in Thrombosis and Haemostasis (2022) Vol. 6, Iss. 3, pp. e12683-e12683
Open Access | Times Cited: 6
Cerebrovascular Disease in COVID-19
James E. Siegler, Savanna Dasgupta, Mohamad Abdalkader, et al.
(2023)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top